MUNENDRA Aalmost 7 years ago
PARP inhibitor improves progression-free survival in patients with advanced breast cancers
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Source: https://medicalxpress.com/news/2018-08-parp-inhibitor-progression-free-survival-patients.htmlRelated posts
Chemotherapy Side EffectsIntravascular Large B-Cell LymphomaThe nurse cares for a patient new to the outpatient chemotherapy clinic. The nurse should include all of the following information instructions concerning the next 48 hours except 1. After using the toilet close the lid and flush twice 2. Avoid kissing loved ones, especially children. 3.Use condom with your partner. 4.If bodily fluids get on your clothes, wash them separately from your family’s.Cancer therapy effects on cell cycleChemotherapy Adverse EffectsAnti-cancer monoclonal antibodiesAnti_cancer small molecule inhibitorsChemotherapy-related Epithelial Necrosis.Chemotherapy-related Ulceration.Extranodal NK/T-Cell Lymphoma, Nasal-Type
